1. Home
  2. Stocks
  3. Ipcalab Share Price

Ipca Laboratories Share Price

Pharmaceuticals Large Cap

₹1,596.80 +11.45 (0.72%)

05 Nov, 2024 22:00

SIP TrendupStart SIP in IPCALAB

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹1,567
  • High
  • ₹1,601
  • 52 Week Low
  • ₹971
  • 52 Week High
  • ₹1,709
  • Open Price₹1,585
  • Previous Close₹1,585
  • Volume149,251

Investment Returns

  • Over 1 Month + 7.07%
  • Over 3 Month + 22.8%
  • Over 6 Month + 19.37%
  • Over 1 Year + 64.65%
SIP Lightning

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 70.2
  • PEG Ratio
  • 4
  • Market Cap Cr
  • 40,512
  • P/B Ratio
  • 5.2
  • Average True Range
  • 42.2
  • EPS
  • 23.6
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 28.78
  • RSI
  • 55.23
  • MFI
  • 34.78

Ipca Laboratories Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations1,565.861,510.621,506.831,662.671,488.71
Total Income From Operations1,565.861,510.621,506.831,662.671,488.71
P/L Before Interest, Excpt. Items & Tax307.31245.68227.36283.77280.34
P/L Before Exceptional Items & Tax287.89221.62200.15245.13249.58
P/L After Tax from Ordinary Activities204.1364.76136.94162.13166.58
Net Profit/Loss For the Period204.1364.76136.94162.13166.58
IndicatorMar 24Mar 23
Revenue From Operations [Gross]6,121.795,777.18
Revenue From Operations [Net]6,121.795,777.18
Total Operating Revenues6,166.465,814.62
Total Revenue6,277.755,925.81
Total Expenses5,322.235,175.32
Profit/Loss Before Tax822.16750.49
Profit/Loss For The Period530.41505.70
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity830.51762.29
Net Cash Used In Investing Activity-1,355.18-709.61
Net Cash Used in Finance Activity-464.88506.38
Net Inc/Dec In Cash And Equivalent-989.55559.06
Cash And Equivalent End Of Year515.281,504.83
IndicatorMar 24Mar 23
Total Share Capital25.3725.37
Total Non-Current Liabilities790.39891.89
Total Current Liabilities1,520.171,677.78
Total Capital And Liabilities8,659.278,446.97
Total Non-Current Assets5,149.383,571.82
Total Current Assets3,509.894,875.15
Total Assets8,659.278,446.97
Indicator20242023
EBIT Margin (%)17.4513.66
Return On Capital Employed (%)15.0711.73
Return On Equity (%)8.358.60
Long Term Debt To Equity (%)8.5411.08
Book Value/Share (INR)250.24231.66
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations2,092.632,033.012,052.862,033.961,587.58
Total Income From Operations2,092.632,033.012,052.862,033.961,587.58
P/L Before Interest, Excpt. Items & Tax314.44242.69254.28269.48283.20
P/L Before Exceptional Items & Tax290.39213.32220.88225.36251.82
P/L After Tax from Ordinary Activities198.982.91222.65137.44166.21
Net Profit/Loss For the Period198.982.91222.65137.44166.21
IndicatorMar 24Mar 23
Revenue From Operations [Gross]7,622.416,206.85
Revenue From Operations [Net]7,622.416,206.85
Total Operating Revenues7,705.046,244.32
Total Revenue7,829.816,369.94
Total Expenses6,879.395,624.65
Profit/Loss Before Tax842.67745.29
Profit/Loss For The Period529.21491.93
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity944.65805.81
Net Cash Used In Investing Activity-1,291.79-725.00
Net Cash Used in Finance Activity-552.55507.24
Net Inc/Dec In Cash And Equivalent-823.19588.05
Cash And Equivalent End Of Year755.791,578.98
IndicatorMar 24Mar 23
Total Share Capital25.3725.37
Total Non-Current Liabilities1,018.64905.29
Total Current Liabilities2,355.641,805.82
Total Capital And Liabilities11,101.288,626.43
Total Non-Current Assets5,562.383,437.16
Total Current Assets5,538.905,189.27
Total Assets11,101.288,626.43
Indicator20242023
EBIT Margin (%)14.1212.66
Return On Capital Employed (%)12.4411.59
Return On Equity (%)8.648.06
Long Term Debt To Equity (%)9.1611.15
Book Value/Share (INR)304.57233.16

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,596.80
+ 11.45 (0.72%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹1,582.69
  • 50 Day
  • ₹1,518.23
  • 100 Day
  • ₹1,431.24
  • 200 Day
  • ₹1,318.23

Resistance and Support

1588.45 Pivot Speed
  • R3 1,644.15
  • R2 1,622.80
  • R1 1,609.80
  • S1 1,575.45
  • S2 1,554.10
  • S3 1,541.10

Is Ipca Laboratories Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies. Ipca Laboratories has an operating revenue of Rs. 8,212.46 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 23% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 45 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results & Interim Dividend
2024-09-30 Others
2024-08-13 Quarterly Results
2024-05-29 Audited Results & Final Dividend
2024-02-14 Quarterly Results
Date Purpose Remarks
2024-11-25 INTERIM Interim Dividend (Revised) split from Rs. 2/- to Re. 1/-.
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

46.3%
28.55%
4.87%
10.83%
0%
6.93%
2.52%
  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,596 As on 05 November, 2024 | 21:46

The Market Cap of Ipca Laboratories is ₹40511.5 Cr As on 05 November, 2024 | 21:46

The P/E ratio of Ipca Laboratories is 70.2 As on 05 November, 2024 | 21:46

The PB ratio of Ipca Laboratories is 5.2 As on 05 November, 2024 | 21:46

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.